Literature DB >> 159913

The allopurinol hypersensitivity syndrome.

G P Lupton, R B Odom.   

Abstract

Hypersensitivity reactions to allopurinol, a drug commonly used in the treatment of hyperuricemia, are being reported with increasing frequency. Of thirty-eight patients reviewed herein (including seven from our hospital and thirty-one from a review of the literature), ten deaths (26%) were related to complications of allopurinol hypersensitivity. Preexisting renal disease was present in 97% of patients, and, in the majority of these, the dosage of allopurinol was not reduced despite instructions contained in the package insert for this drug. At least 78% of patients were taking a thiazide diuretic prior to starting allopurinol therapy. Over 60% of patients had received allopurinol for asymptomatic hyperuricemia. Hallmarks of this hypersensitivity syndrome include a prolonged illness initially manifested by fever, a prominent cutaneous reaction, eosinophilia, hepatic abnormalities, and acute renal failure. Other involvement such as gastrointestinal bleeding is common. The mechanism of the hypersensitivity reaction is not clear, but it may represent an immune complex disease prolonged by the persistence of a currently undefined antigen. Treatment with systemic corticosteroids, often for several months, is usually necessary for the gradual resolution of this potentially fatal syndrome.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 159913     DOI: 10.1016/s0190-9622(79)70031-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  19 in total

1.  Predicting allopurinol response in patients with gout.

Authors:  Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

2.  Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.

Authors:  Alfonso Gutiérrez-Macías; Eva Lizarralde-Palacios; Pedro Martínez-Odriozola; Felipe Miguel-De la Villa
Journal:  BMJ       Date:  2005-09-17

3.  Hypersensitivity reactions to deoxycoformycin.

Authors:  P J O'Dwyer; S A King; E Eisenhauer; J L Grem; D F Hoth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  [Differential indications for uricosuric drugs and allopurinol].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-03-01

5.  Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis.

Authors:  J Auböck; P Fritsch
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-29

6.  Hyperuricemia and gout.

Authors:  B Lo
Journal:  West J Med       Date:  1985-01

7.  Allopurinol hypersensitivity syndrome revisited.

Authors:  T Elasy; D Kaminsky; M Tracy; P S Mehler
Journal:  West J Med       Date:  1995-04

8.  Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.

Authors:  Angelo L Gaffo; Kenneth G Saag
Journal:  Core Evid       Date:  2010-06-15

9.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 10.  Drug-induced severe skin reactions. Incidence, management and prevention.

Authors:  P Wolkenstein; J Revuz
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.